Advanced search
1 file | 1.77 MB Add to list

Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib

Author
Organization
Abstract
Fusions of NTRK (neurotrophic tyrosine receptor kinase) genes with 5' partner genes can result in the expression of chimeric proteins that drive oncogenesis through ligand-independent kinase activation. Despite variable frequencies of NTRK fusions in different tumor types, the fact that they are common to a wide range of cancers raises the possibility of developing tumor-agnostic treatments specifically targeting NTRK fusion products, irrespective of tumor type. The first-generation Trk (tropomyosin receptor kinase) inhibitor, larotrectinib, was the first tumor-agnostic treatment of NTRK fusion-positive cancers in adults and children, to be approved in the European Union. This consensus, developed by a Belgian multidisciplinary expert panel, aims to highlight the unmet medical need associated to NTRK fusion-driven cancer treatment and, based on current knowledge of NTRK fusions and larotrectinib treatment outcome and safety, provide comprehensive guidance to oncologists regarding NTRK fusion-driven cancer diagnostics and the best use of larotrectinib in real-world clinical settings.
Keywords
Oncology, Hematology, Larotrectinib, NTRK gene fusion, Trk inhibitor, Tumor-agnostic, Expert opinion, Oncogene proteins, Protein kinase inhibitors, TRK, FIBROSARCOMA, EFFICACY, CANCERS

Downloads

  • published.pdf
    • full text (Published version)
    • |
    • open access
    • |
    • PDF
    • |
    • 1.77 MB

Citation

Please use this url to cite or link to this publication:

MLA
Awada, Ahmad, et al. “Belgian Expert Consensus for Tumor-Agnostic Treatment of NTRK Gene Fusion-Driven Solid Tumors with Larotrectinib.” CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 169, 2022, doi:10.1016/j.critrevonc.2021.103564.
APA
Awada, A., Berghmans, T., Clement, P. M., Cuppens, K., De Wilde, B., Machiels, J.-P., … Van Cutsem, E. (2022). Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 169. https://doi.org/10.1016/j.critrevonc.2021.103564
Chicago author-date
Awada, Ahmad, Thierry Berghmans, Paul M. Clement, Kristof Cuppens, Bram De Wilde, Jean-Pascal Machiels, Patrick Pauwels, Marc Peeters, Sylvie Rottey, and Eric Van Cutsem. 2022. “Belgian Expert Consensus for Tumor-Agnostic Treatment of NTRK Gene Fusion-Driven Solid Tumors with Larotrectinib.” CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 169. https://doi.org/10.1016/j.critrevonc.2021.103564.
Chicago author-date (all authors)
Awada, Ahmad, Thierry Berghmans, Paul M. Clement, Kristof Cuppens, Bram De Wilde, Jean-Pascal Machiels, Patrick Pauwels, Marc Peeters, Sylvie Rottey, and Eric Van Cutsem. 2022. “Belgian Expert Consensus for Tumor-Agnostic Treatment of NTRK Gene Fusion-Driven Solid Tumors with Larotrectinib.” CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY 169. doi:10.1016/j.critrevonc.2021.103564.
Vancouver
1.
Awada A, Berghmans T, Clement PM, Cuppens K, De Wilde B, Machiels J-P, et al. Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY. 2022;169.
IEEE
[1]
A. Awada et al., “Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib,” CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, vol. 169, 2022.
@article{8730484,
  abstract     = {{Fusions of NTRK (neurotrophic tyrosine receptor kinase) genes with 5' partner genes can result in the expression of chimeric proteins that drive oncogenesis through ligand-independent kinase activation. Despite variable frequencies of NTRK fusions in different tumor types, the fact that they are common to a wide range of cancers raises the possibility of developing tumor-agnostic treatments specifically targeting NTRK fusion products, irrespective of tumor type.

The first-generation Trk (tropomyosin receptor kinase) inhibitor, larotrectinib, was the first tumor-agnostic treatment of NTRK fusion-positive cancers in adults and children, to be approved in the European Union.

This consensus, developed by a Belgian multidisciplinary expert panel, aims to highlight the unmet medical need associated to NTRK fusion-driven cancer treatment and, based on current knowledge of NTRK fusions and larotrectinib treatment outcome and safety, provide comprehensive guidance to oncologists regarding NTRK fusion-driven cancer diagnostics and the best use of larotrectinib in real-world clinical settings.}},
  articleno    = {{103564}},
  author       = {{Awada, Ahmad and Berghmans, Thierry and Clement, Paul M. and Cuppens, Kristof and De Wilde, Bram and Machiels, Jean-Pascal and Pauwels, Patrick and Peeters, Marc and Rottey, Sylvie and Van Cutsem, Eric}},
  issn         = {{1040-8428}},
  journal      = {{CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY}},
  keywords     = {{Oncology,Hematology,Larotrectinib,NTRK gene fusion,Trk inhibitor,Tumor-agnostic,Expert opinion,Oncogene proteins,Protein kinase inhibitors,TRK,FIBROSARCOMA,EFFICACY,CANCERS}},
  language     = {{eng}},
  pages        = {{8}},
  title        = {{Belgian expert consensus for tumor-agnostic treatment of NTRK gene fusion-driven solid tumors with larotrectinib}},
  url          = {{http://dx.doi.org/10.1016/j.critrevonc.2021.103564}},
  volume       = {{169}},
  year         = {{2022}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: